Merck KGaA, headquartered in Darmstadt, Germany, Reveals Initiation of Phase III Trial with Oral Cladribine for Treating Generalized Myasthenia Gravis (gMG), Marking First Patient Administration.

Biocon Biologics Achieves Market Access for Bmab 1200, a Biosimilar Candidate Akin to Stelara®, Across Europe, the UK, Canada, and Japan.

Jeune Aesthetics Reveals Encouraging Interim Safety & Efficacy Outcomes for KB301 in Phase 1, Targeting Lateral Eye Creases & Active Décolletage Wrinkles Reduction.

Neurocrine Biosciences Announces Encouraging Phase 2 Outcomes for NBI-1117568 in Adult Schizophrenia Patients, Demonstrating Potential Efficacy.

8.26-9.1 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Novartis' biannual Leqvio® showed significant and meaningful LDL-C reduction as a solo treatment for patients with low to moderate ASCVD risk.

Merck Begins Phase 3 Study of Bomedemstat, an Experimental Drug for Specific Essential Thrombocythemia Patients.

Cantargia (Cantargia AB, Nasdaq Stockholm: CANTA) has updated the anticipated schedules for nadunolimab clinical studies.

Centessa Pharmaceuticals Unveils Late-Breaking Poster on Non-Human Primate Data for ORX142, a New Orexin Receptor 2 (OX2R) Agonist.

Find Therapeutics Announces FDA Approval for FTX-101 Phase 1 Clinical Trial in Chronic Optic Neuropathy Treatment.

The European Commission has authorized the use of Astellas’ PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as an initial treatment for advanced urothelial carcinoma.

Yunovia revealed on the 26th that the Korean MFDS has approved the IND application for a Phase 1 MAD study of ID110521156.